U.O. Malattie Endocrine del Ricambio e della Nutrizione, Azienda Ospedaliero-Universitaria Policlinico Giaccone
Welcome,         Profile    Billing    Logout  
 2 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Giordano, Carla
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
PHOTOFINISH, NCT05613985: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers

Recruiting
N/A
146
Europe
Usual Care alone, System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Diabetic Foot Infection
06/24
12/24
Genovese, Stefano
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
CARDT1, NCT06290544: Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus

Recruiting
N/A
200
Europe
Standard of care plus additional examinations
Centro Cardiologico Monzino
Diabetes Mellitus, Type 1, Cardiovascular Diseases
07/26
07/26
PHOTOFINISH, NCT05613985: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers

Recruiting
N/A
146
Europe
Usual Care alone, System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Diabetic Foot Infection
06/24
12/24
CV-PREVITAL, NCT05339841: Italian Digital Primary Cardiovascular Prevention Study

Active, not recruiting
N/A
27520
Europe
Mobile health application, mHealth app
Centro Cardiologico Monzino, Istituto Auxologico Italiano, Humanitas Hospital, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, IRCCS Multimedica, Neuromed IRCCS, IRCCS Policlinico S. Donato, Istituti Clinici Scientifici Maugeri SpA, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Ospedale Policlinico San Martino, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS San Raffaele Roma
Healthy Population
06/29
12/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Giordano, Carla
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
PHOTOFINISH, NCT05613985: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers

Recruiting
N/A
146
Europe
Usual Care alone, System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Diabetic Foot Infection
06/24
12/24
Genovese, Stefano
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
CARDT1, NCT06290544: Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus

Recruiting
N/A
200
Europe
Standard of care plus additional examinations
Centro Cardiologico Monzino
Diabetes Mellitus, Type 1, Cardiovascular Diseases
07/26
07/26
PHOTOFINISH, NCT05613985: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers

Recruiting
N/A
146
Europe
Usual Care alone, System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Diabetic Foot Infection
06/24
12/24
CV-PREVITAL, NCT05339841: Italian Digital Primary Cardiovascular Prevention Study

Active, not recruiting
N/A
27520
Europe
Mobile health application, mHealth app
Centro Cardiologico Monzino, Istituto Auxologico Italiano, Humanitas Hospital, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, IRCCS Multimedica, Neuromed IRCCS, IRCCS Policlinico S. Donato, Istituti Clinici Scientifici Maugeri SpA, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Ospedale Policlinico San Martino, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS San Raffaele Roma
Healthy Population
06/29
12/29

Download Options